Targeting IL-6 to prevent cardiac allograft rejection.

ABSTRACT: Outcomes following heart transplantation remain suboptimal with acute and chronic rejection being major contributors to poor long-term survival. IL-6 is increasingly recognized as a critical pro-inflammatory cytokine involved in allograft injury and has been shown to play a key role in regulating the inflammatory and alloimmune responses following heart transplantation. Therapies that inhibit IL-6 signaling have emerged as promising strategies to prevent allograft rejection. Here, we review experimental and pre-clinical evidence that supports the potential use of IL-6 signaling blockade to improve outcomes in heart transplant recipients.

SUBMITTER: Miller CL 

PROVIDER: S-EPMC10191185 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature